NCT05000294 2026-06-05Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesUniversity of FloridaPhase 1/2 Recruiting29 enrolled
NCT04471727 2026-02-24MK-6070-001Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 1/2 Active not recruiting232 enrolled